M. Gu and J. Shao contributed equally to this study. Author's contributions: MG and JFS carried out the genotyping analysis, the statistical analysis and drafted the manuscript. ZDZ and LXQ participated in the study design. ZQZ and QH provided clinical biospecimens and participated in coordination.
Original Article: Clinical Investigation
Genetic variants of the cytochrome P450 and glutathione S-transferase associated with risk of bladder cancer in a south-eastern Chinese population
Article first published online: 9 JAN 2008
2008 The Japanese Urological Association
International Journal of Urology
Volume 15, Issue 3, pages 216–221, March 2008
How to Cite
Shao, J., Gu, M., Zhang, Z., Xu, Z., Hu, Q. and Qian, L. (2008), Genetic variants of the cytochrome P450 and glutathione S-transferase associated with risk of bladder cancer in a south-eastern Chinese population. International Journal of Urology, 15: 216–221. doi: 10.1111/j.1442-2042.2007.01915.x
- Issue published online: 26 FEB 2008
- Article first published online: 9 JAN 2008
- Received 5 January 2007; accepted 9 September 2007.
- bladder cancer;
- Chinese population;
- genetic variant;
- molecular epidemiology;
Objective: To evaluate the association between genetic polymorphisms of CYP2E1 RsaI and GSTM1 and development of bladder cancer in a south-eastern Han Chinese population.
Methods: We hypothesized that the CYP2E1-1019T>A and GSTM1 polymorphisms were associated with risk of bladder cancer. In a hospital-based case-control study of 202 case patients with newly diagnosed bladder transitional cell carcinoma and 272 cancer-free controls frequency-matched by the age and sex, we genotyped these two polymorphisms using a polymerase chain reaction-restriction fragment length polymorphism method.
Results: We found that the GSTM1 null genotype was associated with an increased risk of bladder cancer (adjusted odds ratio [OR] = 1.73, 95% confidence interval [CI] = 1.17–2.56) compared with those with the non-null genotype, but the CYP2E1-1019T>A polymorphisms did not show any association. In the stratification analysis of the GSTM1 polymorphism, we found that the increased risk was more pronounced among subgroups aged ≤60 years (OR = 2.02, 95% CI = 1.08–3.77), smokers (OR = 1.94, 95% CI = 1.11–3.38) and non-drinkers (OR = 3.86, 95% CI = 1.28–11.60).
Conclusion: GSTM1 polymorphism (but not CYP2E1 RsaI polymorphism) appears to contribute to the etiology of bladder cancer in a south-eastern Chinese population.